SEQURNA

Stockholm · est. 2022 · website↗

Registered as SEQURNA AB

Introducing next-generation RNase inhibitors - ideal for single-cell and in situ RNA-sequencing SEQURNA's RNase inhibitor makes RNA work and sequencing pipelines more accessible, affordable, and sustainable. Unlike competitors’ recombinant RNase inhibitors, the SEQURNA inhibitor is thermostable and can be shipped and stored at room temperature without affecting performance. These features not only simplify shipping and storage logistics, eliminate batch effects, and reduce costs for the user but also enable new and simplified workflows and novel laboratory protocols, including heat cycles. Propel your biotech business or research, and choose a more environmentally sustainable option for RNase inhibition in your RNA-seq workflows, by becoming an early user of SEQURNA’s RNase inhibitor. Our R&D team is keen to assist and advice in the transition. Find out more at www.sequrna.com or email us at info@sequrna.com

Share feedback about SEQURNA

What kind?
Or email alex@stackholm.dev.
SurvivalStrongEquity ratio 82%
SectorEnergy, climate & industry
Employees2registry FY2025
Age4 yearsest. 2022
LanguageEnglish site
Open rolesNot on file yet

Filed financials

Filed with a public registry

Filed with Bolagsverket. The legal entity, not the group.

Headcount grew by 1 person in 2025.

Fiscal yearRevenueResultEmployeesCashEquityTotal assetsFlags
FY20256.7 MSEK2.1 MSEK213 MSEK14 MSEK17 MSEKNone
FY20242.6 MSEK1.3 MSEK19.7 MSEK12 MSEK13 MSEKNone
FY2023under 0.1 MSEK----0.8 MSEKNone

Open roles

SEQURNA hires through LinkedIn, which isn't read here.

SEQURNA on LinkedIn Jobs↗

Registered business activity (SNI)

Filed with a public registry

Standard industry classification codes as filed with Bolagsverket.

Tillverkning av övriga kemiska produkterAnnan naturvetenskaplig och teknisk forskning och utveckling

Companies like this one

Work here?

Nobody has answered yet. Same questions for every company.

Answer for this company